Recipharm
Recipharm is a contract development and manufacturing organisation (CDMO).
Financials
Estimates*
SEK | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|---|
Revenues | 4.6b | 5.4b | 6.4b | 7.5b | 11.1b | 11.7b | 12.3b |
% growth | 25 % | 18 % | 19 % | 17 % | 49 % | 5 % | 5 % |
EBITDA | 727m | 730m | 994m | 1.1b | 1.8b | 2.2b | 2.4b |
% EBITDA margin | 16 % | 14 % | 16 % | 15 % | 16 % | 19 % | 19 % |
Profit | - | (171m) | 159m | 343m | 339m | 571m | 701m |
% profit margin | - | (3 %) | 2 % | 5 % | 3 % | 5 % | 6 % |
EV / revenue | - | 1.8x | 1.8x | 1.9x | 2.8x | - | - |
EV / EBITDA | - | 13.2x | 11.5x | 12.7x | 17.4x | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | IPO | |
SEK1.5b | Post IPO Debt | ||
N/A | $32.0m | Post IPO Equity | |
Total Funding | - |
Recent News about Recipharm
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Recipharm
EditACQUISITION by Recipharm Feb 2022
ACQUISITION by Recipharm Nov 2014
ACQUISITION by Recipharm Feb 2016
ACQUISITION by Recipharm Aug 2014
ACQUISITION by Recipharm Feb 2022
ACQUISITION by Recipharm Apr 2016
ACQUISITION by Synokem Pharmaceuticals Dec 2023
ACQUISITION by Recipharm Feb 2022